<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359281</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-002</org_study_id>
    <secondary_id>Aegerion 002 PK study</secondary_id>
    <nct_id>NCT00359281</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents</brief_title>
  <official_title>A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II, open-label research study was conducted in 129 healthy volunteers. Each
      subject will be given one initial oral dose of one of 7 FDA-approved medications (probe
      drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10
      or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug
      that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return
      in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10)
      or fifteen (15) subjects.

      Safety, pharmacokinetic and pharmacodynamic assessments will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary: To evaluate the effects of low and high doses of AEGR-733 on the pharmacokinetics of
      6 FDA-approved medications that are likely to be used in combination with AEGR-733 as
      assessed by:

      â€¢ Pharmacokinetic parameters: Cmax, Tmax, T1/2, and AUC (area under the curve).

      Secondary: To evaluate the safety of AEGR-733 in combination with other lipid lowering agents
      in healthy subject as assessed by:

        -  Changes in associated liver enzymes AST, ALT and, Alkaline Phosphatase, &amp; Total
           Bilirubin.

        -  Changes in all reported adverse events.

        -  To evaluate the effects of AEGR-733 in combination with other lipid lowering agents on
           the following lipids and lipoproteins: TC, LDL-C, VLDL, TG, HDL-C, ApoB and ApoAI.

      4.0 STUDY DESIGN AND RATIONALE

      4.1 STUDY DESIGN This is a single-center, phase II, clinical trial consisting of a eight (8)
      day open-label phase to assess the pharmacokinetic drug interactions of AEGR-733 on 6 probe
      drugs in healthy volunteers, followed by a one week safety visit. 105 subjects will be
      enrolled into this fixed-sequenced research study. Eligible subjects based on the screening
      visit will come to the GCRC for an inpatient visit (25-36 hr depending on if they come in
      evening before study day 1 or morning of). On the morning of study day 1, subjects will be
      assigned to one of 6 probe drugs(A-H below) and will take one dose of this medication. Timed
      blood samples will be drawn just before the administration of the probe drug and during the
      following times after drug administration (1,2,3,4,5,6,8,10,12,18, and 24 hrs). Prior to
      discharge after the 24 h blood sample, subjects will take an oral dose of AEGR-733 at 10 mg
      or 60 mg. Subjects will be given a 5 day supply of AEGR-733 at 10 mg or 60 mg to be taken
      once daily in the morning for the next 5 days (through day 7). On study day 8, subjects will
      take a final dose of AEGR-733 at 10 mg or 60 mg (total doses= 7) simultaneously with the same
      probe drug they took on day 1. Timed blood samples will be drawn just before the
      administration of the probe drug and AEGR-733 as well as 1,2,3,4,5,6,8,10,12,18, and 24 hours
      after study drug administration. After the 24 hour blood sample, subjects will be discharged.
      15 subjects who participate in this study will receive dextromethorphan as the probe drug,
      which requires urine collection for 8 hours post dose. Blood for pharmacokinetic samples will
      not be collected on these subjects. Subjects receiving dextromethorphan may leave after the 8
      hour urine collection at visits 2 and 3 (referred to as the inpatient visits). All subjects
      will come back 1 week later for a final visit to check safety lab parameters including liver
      transaminases and total bilirubin. Subjects will be instructed to abstain from drinking any
      alcoholic beverages once screened until study completion. Subjects who are not willing to
      comply with these requests will not be enrolled.

      The FDA-approved lipid-lowering therapies will include:

      A) Atorvastatin, 20 mg (n=15)and AEGR-733 10 mg B) Ezetimibe, 10 mg (n=10)and AEGR-733 10 mg
      C) Simvastatin, 20 mg (n=15)and AEGR-733 10 mg D) Rosuvastatin, 20 mg (n=10)and AEGR-733 10
      mg E) Micronized fenofibrate, 145 mg (n=10)and AEGR-733 10 mg F) Atorvastatin, 20 mg (n=15)
      and AEGR-733 60 mg G) Rosuvastatin, 20 mg (n=15) and AEGR-733 60 mg H) Dextromethorphan, 30
      mg (n=15) and AEGR-733 60 mg I) Extended Release Niacin, 1000 mg (n=20) and AEGR-733 10 mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)</measure>
    <time_frame>0 to 24 hour</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Simvastatin</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Simvastatin Acid</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Total Ezetimibe</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Rosuvastatin (Lomitapide 10 mg)</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Fenofibric Acid</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Atorvastatin Acid (Lomitapide 60 mg)</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Rosuvastatin (Lomitapide 60 mg)</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Nicotinic Acid</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t Nicotinuric Acid</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline to Day 8</time_frame>
    <description>Percent change from Baseline in LDL-C</description>
  </secondary_outcome>
  <enrollment type="Actual">125</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Simvastatin 20 mg and AEGR-733 10 mg or 60 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg and AEGR-733 10 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>Micronized Fenofibrate 145 mg and AEGR-733 10 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan</intervention_name>
    <description>Dextromethorphan 30 mg and AEGR-733 10 mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended Release Niacin</intervention_name>
    <description>1000 mg ER niacin and AEGR-733 10 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males and non-pregnant/non-lactating female subjects between the ages of 18 and 70 who are
        in good overall health.

        To be eligible for enrollment in this study, patients must meet all of the following
        criteria:

          1. Men and women between the ages of 18 and 70

          2. Women of child-bearing potential, that is, women not surgically sterilized and between
             menarche and 1 year post menopause, must test negative for pregnancy at the time of
             enrollment based on a urine pregnancy test and agree to use a reliable method of
             non-medication birth control (for example, a reliable barrier method of birth control
             [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms
             with contraceptive foam; intrauterine devices]; partner with vasectomy; or abstinence)
             during the study and for one month following the last dose of study drug.

          3. Subjects must be in good overall health

          4. Subjects must be able to comprehend and willing to provide a signed IRB approved
             Informed Consent Form.

          5. Subjects must be willing to comply with all study-related procedures.

        Exclusion Criteria:

          1. Known atherosclerotic cardiovascular disease, including coronary disease,
             cerebrovascular disease, or peripheral vascular disease

          2. History of diabetes mellitus or fasting glucose &gt; 126 mg/dL at the screening visit.

          3. History of a non-skin malignancy within the previous 5 years

          4. Renal insufficiency as defined by creatinine &gt; 1.3 mg/dl

          5. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory
             condition

          6. History of hypertension

          7. Known coagulopathy and /or elevated PT/PTT &gt;1.5 x ULN

          8. Oral history of HIV positive

          9. Patients who have undergone any organ transplant

         10. Known active fibrotic or cirrhotic disease; ALT or AST &gt; 1.5x ULN

         11. Any major surgery within the previous 3 months

         12. Individuals who currently use tobacco products or have done so in the previous 30 days

         13. History of drug abuse (&lt; 3 years)

         14. Regular use of alcoholic beverages (&gt; 7 drinks/day)

         15. Subjects who do not agree to abstain from consuming alcoholic beverages during the
             entire study duration.

         16. Body mass index (BMI) &gt; 30 kg/m2 or &lt; 18.5 kg/m2

         17. Participation in an investigational drug study within 6 weeks prior to the screening
             visit

         18. Serious or unstable medical or psychological conditions that, in the opinion of the
             investigator, would compromise the subject's safety or successful participation in the
             study will be excluded.

         19. Currently taking any prescription, including oral contraceptives, or OTC medication
             regularly that cannot be stopped for at least 30 days prior to enrollment until
             completion of the study

         20. Regular consumers of grapefruit juice, or have taken any medications known to be
             metabolized by CYP 3A4 within 4 weeks prior to the screening visit (ie. SSRIs,
             anti-fungals, anti-biotics, etc)

         21. History of myalgia with a statin or unknown hypersensitivity to any statin, zetia,
             AEGR-733, or fenofibrate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2006</study_first_submitted>
  <study_first_submitted_qc>August 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2006</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>January 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed from 19 May 2006 to 20 November 2007 at 1 medical clinic within the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe 10 mg + Lomitapide 10 mg</title>
          <description>One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="P4">
          <title>Rosuvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="P5">
          <title>Fenofibrate 145 mg + Lomitapide 10 mg</title>
          <description>One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="P6">
          <title>Atorvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="P7">
          <title>Rosuvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="P8">
          <title>Dextrometh-rophan 30 mg + Lomitapide 60 mg</title>
          <description>One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="P9">
          <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
          <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe 10 mg + Lomitapide 10 mg</title>
          <description>One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="B4">
          <title>Rosuvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="B5">
          <title>Fenofibrate 145 mg + Lomitapide 10 mg</title>
          <description>One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="B6">
          <title>Atorvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="B7">
          <title>Rosuvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="B8">
          <title>Dextrometh-rophan 30 mg + Lomitapide 60 mg</title>
          <description>One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="B9">
          <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
          <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="15"/>
            <count group_id="B7" value="18"/>
            <count group_id="B8" value="15"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="7"/>
                    <measurement group_id="B2" value="29" spread="12"/>
                    <measurement group_id="B3" value="29" spread="9"/>
                    <measurement group_id="B4" value="31" spread="13"/>
                    <measurement group_id="B5" value="24" spread="3"/>
                    <measurement group_id="B6" value="27" spread="8"/>
                    <measurement group_id="B7" value="31" spread="13"/>
                    <measurement group_id="B8" value="27" spread="9"/>
                    <measurement group_id="B9" value="29" spread="11"/>
                    <measurement group_id="B10" value="28" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg)</description>
        <time_frame>0 to 24 hour</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 10 mg)</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.97" lower_limit="98.42" upper_limit="125.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Percent change from Baseline in LDL-C</description>
        <time_frame>Baseline to Day 8</time_frame>
        <population>Intention To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe 10 mg + Lomitapide 10 mg</title>
            <description>One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Rosuvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
          <group group_id="O5">
            <title>Fenofibrate 145 mg + Lomitapide 10 mg</title>
            <description>One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg</description>
          </group>
          <group group_id="O6">
            <title>Atorvastatin 20 mg + Lomitapide 60 mg</title>
            <description>One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg</description>
          </group>
          <group group_id="O7">
            <title>Rosuvastatin 20 mg + Lomitapide 60 mg</title>
            <description>One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg</description>
          </group>
          <group group_id="O8">
            <title>Dextrometh-rophan 30 mg + Lomitapide 60 mg</title>
            <description>One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg</description>
          </group>
          <group group_id="O9">
            <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
            <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Percent change from Baseline in LDL-C</description>
          <population>Intention To Treat</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.99" spread="14.47"/>
                    <measurement group_id="O2" value="-26.43" spread="17.77"/>
                    <measurement group_id="O3" value="-28.36" spread="12.53"/>
                    <measurement group_id="O4" value="-41.74" spread="10.37"/>
                    <measurement group_id="O5" value="-20.12" spread="25.56"/>
                    <measurement group_id="O6" value="-66.02" spread="15.18"/>
                    <measurement group_id="O7" value="-63.20" spread="18.59"/>
                    <measurement group_id="O8" value="-46.07" spread="33.12"/>
                    <measurement group_id="O9" value="-20.89" spread="15.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Simvastatin</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Simvastatin</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.25" lower_limit="143.19" upper_limit="183.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Simvastatin Acid</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Simvastatin Acid</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for simvastatin acid</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.76" lower_limit="109.65" upper_limit="175.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Total Ezetimibe</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg + Lomitapide 10 mg</title>
            <description>One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Total Ezetimibe</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for total ezetimibe</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.71" lower_limit="92.62" upper_limit="120.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Rosuvastatin (Lomitapide 10 mg)</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg)</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg + Lomitapide 10 mg</title>
            <description>One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Rosuvastatin (Lomitapide 10 mg)</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 10 mg)</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.05" lower_limit="86.00" upper_limit="121.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Fenofibric Acid</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate 145 mg + Lomitapide 10 mg</title>
            <description>One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Fenofibric Acid</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for fenofibric acid</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.62" lower_limit="82.76" upper_limit="97.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Atorvastatin Acid (Lomitapide 60 mg)</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg)</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 20 mg + Lomitapide 60 mg</title>
            <description>One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Atorvastatin Acid (Lomitapide 60 mg)</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for atorvastatin acid (Lomitapide 60 mg)</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.32" lower_limit="133.76" upper_limit="173.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Rosuvastatin (Lomitapide 60 mg)</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg)</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 20 mg + Lomitapide 60 mg</title>
            <description>One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Rosuvastatin (Lomitapide 60 mg)</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for rosuvastatin (Lomitapide 60 mg)</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.21" lower_limit="111.56" upper_limit="156.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Nicotinic Acid</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
            <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Nicotinic Acid</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinic acid</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.22" lower_limit="78.28" upper_limit="155.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t Nicotinuric Acid</title>
        <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
            <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t Nicotinuric Acid</title>
          <description>Geometric Mean Ratio ln(AUC0-t) Day 8/Day 1 for nicotinuric acid</description>
          <population>Pharmacokinetic</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.15" lower_limit="59.82" upper_limit="104.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug (Day 1) to 14 days after the first dose (Day 15)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Simvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Simvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe 10 mg + Lomitapide 10 mg</title>
          <description>One dose oral Ezetimibe 10 mg, Lomitapide 10 mg once daily 6 days then one dose oral Ezetimibe 10 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="E4">
          <title>Rosuvastatin 20 mg + Lomitapide 10 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 10 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="E5">
          <title>Fenofibrate 145 mg + Lomitapide 10 mg</title>
          <description>One dose oral micronized Fenofibrate 145 mg, Lomitapide 10 mg once daily 6 days then one dose oral micronized Fenofibrate 145 mg and Lomitapide 10 mg</description>
        </group>
        <group group_id="E6">
          <title>Atorvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Atorvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Atorvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="E7">
          <title>Rosuvastatin 20 mg + Lomitapide 60 mg</title>
          <description>One dose oral Rosuvastatin 20 mg, Lomitapide 60 mg once daily 6 days then one dose oral Rosuvastatin 20 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="E8">
          <title>Dextrometh-rophan 30 mg + Lomitapide 60 mg</title>
          <description>One dose oral Dextrometh-rophan 30 mg, Lomitapide 60 mg once daily 6 days then one dose oral Dextrometh-rophan 30 mg and Lomitapide 60 mg</description>
        </group>
        <group group_id="E9">
          <title>ER Niacin 1000 mg + Lomitapide 10 mg</title>
          <description>One dose oral ER Niacin 1000 mg, Lomitapide 60 mg once daily 6 days then one dose oral ER Niacin 1000 mg and Lomitapide 60 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Sumeray, MD, Chief Medical Officer</name_or_title>
      <organization>Aegerion Pharmaceuticals</organization>
      <phone>617-500-7867</phone>
      <email>msumeray@aegerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

